Department of Health and Human Services assistant secretary for preparedness and response Dr. Nicole Lurie thinks that the efforts to combat this years H1N1 flu will permanently improve the response to future pandemics.
Researchers are now reporting that an experimental mixture of the H5N1 avian flu and the H3N2 human flu did not seem to be easily transmissable. Researchers tested the experimental hybrid strain in ferrets, whose upper respiratory tract and lungs are similar to humans. Copyright 2006 Insidesurgery.com
British pharmaceutical giant GlaxoSmithKline has reported that they have achieved an 80% response rate in volunteers receiving an experimental vaccine to combat the H5N1 avian influenza strain. Of importance is that the immune response was secondary to two relatively small doses of 3.8 micrograms of the antigen. Copyright 2006 Insidesurgery.com
InsideSurgery RSS Feed